28 results about "Specific igg" patented technology

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The invention relates to the technical field of detection kits, in particular to a milk specificity IgG antibody detection kit which comprises a detection kit body, a storage hole is formed in the bottom end of the detection kit body, the top end of the storage hole is communicated with a discharging cavity, and a feeding pipe fixedly penetrates through the middle of the side face of the detection kit body; the feeding pipe injects a sample solution into the discharging cavity, an extended cleaning mechanism is arranged on the inner wall of the storage hole, the top end of the discharging cavity is communicated with a detection cavity, and a cleaning mechanism, a sampling mechanism and a rotary detection mechanism are arranged on the inner wall of the detection cavity. The extended cleaning mechanism comprises a storage column arranged on the inner wall of the storage hole; the device can ensure that the cleaning scraping plate is continuously and tightly attached to the inner wall of the discharging cavity, the scraping efficiency is guaranteed, the cleaning quality is improved, the cleaning scraping plate can be stored and hidden after cleaning is completed, deformation caused by collision with a sampling rod during sampling is avoided, and the cleaning performance of the cleaning scraping plate is maintained.

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

Provided are an RSV F protein mutant, and a preparation method therefor and a use thereof. Provided is a mutant protein, the mutant protein being in the form of a monomer or a trimer, wherein the trimer is formed by three monomeric mutant proteins; the monomeric mutant protein is a fusion protein comprising a first polypeptide element derived from an RSV F protein and a trimerization domain element; in the first polypeptide element, a Pep27 fragment of the RSV F protein is replaced with a linker sequence; and the monomeric and trimeric mutant proteins are both bound by an antibody that specifically recognizes RSV pre-F. The mutant protein can stably remain in a pre-fusion state, can induce the production of specific IgG antibodies and neutralizing antibodies, has excellent immunogenicity, and can be used for the development of RSV vaccines.

An agent including a glycan-specific IgG antibody moiety, a cellular receptor binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein (ASGPR) receptors of hepatocytes or other cell receptors which are on the surface degrading cells in a patient or subject, and optionally, a linker moiety connecting the glycan-specific IgG antibody moiety and the cellular receptor binding moiety.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The present application belongs to the field of biomedical technology, and more particularly relates to the application of Periplaneta americana polypeptide HFDT1 as an immune adjuvant in the preparation of a brucellosis vaccine. The present application uses Brucella OMP10, BP26 and L7 / L12 proteins in combination with HFDT1 to induce mice to produce higher titers of anti-OMP10, BP26 and L7 / L12 protein specific IgG antibodies, and the titers increase with the increase in the number of immunizations, while promoting the body to produce mixed Th1 / Th2 type cellular immune responses and stimulating the proliferation and differentiation of mouse spleen T and B cells, and also facilitating mass production. The Periplaneta americana polypeptide HFDT1 described in the present application is obtained by convenient mass synthesis, and can be used as a novel small molecule immune adjuvant to enhance specific immune responses of the body.

The invention provides polynucleotide for coding an RSV (Respiratory Syndrome Virus) pre-fusion F protein and application of the polynucleotide in an mRNA (Messenger Ribonucleic Acid) vaccine. The sequence of the polynucleotide is as shown in SEQ ID No: 1. Experiments prove that the antigen-specific IgG titer of the polynucleotide, the vaccine and the pharmaceutical composition provided by the invention is 2-4 times that of an unoptimized sequence, so that more efficient expression of target protein in vivo is prompted, and meanwhile, the geometric mean titer value of a neutralizing antibody is also higher than that of the unoptimized sequence, so that good immunogenicity is prompted. The GMT value and the antigen specificity IFN-gamma, IL-5 and IL-17A levels of the neutralizing antibody generated by induction of the RSV mRNA vaccine provided by the invention are obviously higher than those of a control group in the prior art, so that the RSV mRNA vaccine has excellent application prospects.

This invention relates to the field of biomedical technology, specifically disclosing a three-component recombinant subunit vaccine composition for Mycoplasma pneumoniae and its application. The vaccine composition comprises key antigenic proteins of Mycoplasma pneumoniae (MP): P1 protein, P40 / 90 protein, and an E132A attenuated mutant of community-acquired respiratory distress syndrome (CARDS) toxin (CARDS-Mut), optionally combined with Al(OH)3 single adjuvant or Al(OH)3+CPG double adjuvant. The recombinant protein was successfully purified using a prokaryotic expression system, and validated in a mouse model. The vaccine induces high-titer specific IgG antibodies, significantly alleviates lung tissue pathological damage, reduces bacterial load, and inhibits inflammatory factor secretion after challenge, with good safety. This invention solves the problem of high toxicity of CARDS toxin, providing an efficient and safe vaccine strategy for the prevention and control of MP infection.

The invention discloses a coupling protein as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, in-vitro self-coupling of the rotavirus VP8 protein and the norovirus VP1 protein is realized by utilizing a Spatier-Spytag system, the prepared coupled protein can induce a neutralizing antibody with higher titer aiming at the rotavirus, and the immunogenicity of the norovirus VP1 protein is not influenced; the immunized animal / human body can generate a high-titer specific IgG binding antibody, a serum blocking antibody and a neutralizing antibody aiming at the two viruses. The coupling protein has a wide application prospect in vaccines for resisting infant diarrhea viruses (norovirus and rotavirus).

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

The invention provides a novel adjuvant subunit rabies virus vaccine as well as a preparation method and application thereof, the vaccine takes a rabies virus (RABV) glycoprotein extracellular domain prepared by a gene recombination technology as an antigen, and takes a combination of CpG oligodeoxynucleotide and QS21 as an adjuvant. A contrast experiment is carried out on the vaccine, an LNP-mRNA-G-H270P vaccine, a commercial inactivated vaccine and an aluminum adjuvant subunit vaccine, and the result shows that the vaccine can induce a remarkably higher RABV-G specific IgG antibody and virus neutralizing antibody titer, and the humoral immune response is superior to that of other vaccines; meanwhile, moderate and effective Th1 type cell immune response can be induced, so that protective immunity can be supported; 100% protection is achieved in a lethal RABV attack experiment, and the protection effect is equivalent to that of an mRNA vaccine and is remarkably superior to that of an aluminum adjuvant vaccine and a commercial inactivated vaccine. The vaccine provided by the invention has a controllable immune activation mechanism and relatively high safety, avoids the storage risk and excessive inflammatory response of a nucleic acid technology, and is a more reliable and universal choice in the current vaccine technology.

The invention belongs to the technical field of biological detection, and discloses a food specific IgG antibody detection reagent card, a food specific IgG antibody detection kit, a preparation method and application. The food specific IgG antibody detection reagent card prepared by the preparation method can qualitatively detect and analyze the specific IgG antibody in human serum or fingertip whole blood based on immunochromatography. The kit prepared from the reagent card is used for detecting the food specific IgG antibody, has the characteristics of high detection sensitivity, strong specificity, simplicity in operation, cost saving and the like, and has a great market and a good application prospect.

The application belongs to the technical field of biology and discloses a fusion protein S1-linker-Ferritin nanoparticle, wherein the fusion protein S1-linker-Ferritin nanoparticle comprises S1 protein of porcine epidemic diarrhea virus, a ferritin linker and Ferritin protein; the nucleotide sequence of the fusion protein S1-linker-Ferritin nanoparticle is shown in SEQ ID NO. 1, and the amino acid sequence is shown in SEQ ID NO. 2; the fusion protein S1-linker-Ferritin nanoparticle is prepared into a vaccine, and the specific IgG antibody level and the neutralizing antibody level of mice immunized by the vaccine are higher than those of mice immunized by a commercial inactivated vaccine (p<0.01), the number of CD3 + CD4 + , CD3 + CD8 + T cells produced by the mice immunized by the vaccine are higher than those of the mice immunized by the commercial inactivated vaccine. Meanwhile, the application discloses a preparation method of the fusion protein S1-linker-Ferritin nanoparticle and a vaccine containing the fusion protein S1-linker-Ferritin nanoparticle.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The invention discloses a bovine parainfluenza virus 3A and 3C type multi-epitope antigen peptide as well as a compound and application thereof. The amino acid sequences of the multi-epitope antigen peptides BPIV-3A and BPIV-3C are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 3, and the multi-epitope antigen peptides are formed by connecting CTL epitopes, HTL epitopes and B cell epitopes screened from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immune tests show that the antigen peptide and the compound thereof can effectively stimulate a body to generate a specific IgG antibody and a neutralizing antibody, induce immune response of Th1 type cells, effectively eliminate viruses and relieve lung tissue lesions, and show good immunogenicity and protection effect. The invention provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention discloses an Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine and an application of the Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine. The preparation method comprises the following steps: replacing a fifth hypervariable region of an HAdV-4 hexon in an HAdV-4 genome with a second hypervariable region of an HAdV-55 hexon to obtain a recombinant adenovirus Ad4-55; and replacing the first hypervariable region of the HAdV-7 hexon in the HAdV-7 genome with the first hypervariable region of the HAdV-3 hexon, so as to obtain the recombinant adenovirus Ad7-3. And mixing the recombinant adenovirus Ad4-55 and the recombinant adenovirus Ad7-3 to obtain the tetravalent recombinant adenovirus vaccine. Experiments prove that when the tetravalent recombinant adenovirus vaccine prepared by the invention is used for immunizing mice, high-level specific IgG antibodies and neutralizing antibodies can be induced. According to the present invention, the important application value is provided for the prevention and control of HAdV-3, HAdV-7, HAdV-4 and HAdV-55.

The invention relates to a hepatitis A virus (HAV) fusion protein as well as a preparation method and application thereof, prokaryotic expression and purification are carried out based on connection and fusion of main antigen regions of HAV capsid proteins VP1 and VP3, a high-purity HAV-rVP13 fusion protein is obtained, the HAV-rVP13 fusion protein is used as a coating antigen, and an ELISA detection method for an HAV specific IgG antibody is established. By establishing an enterprise calibrator and a quality control product and calibrating by a national HAV specific IgG standard product, the established ELISA detection method can quantitatively determine the concentration of the HAV specific IgG antibody in human plasma / serum, has very high sensitivity and specificity, and can be used for quantitative detection of the HAV IgG antibody in a human plasma / serum sample.

The invention relates to the technical field of biological medicines, in particular to a mycoplasma hyopneumoniae extracellular vesicle, a vaccine and a preparation method and application of the mycoplasma hyopneumoniae extracellular vesicle. The diameter of the mycoplasma hyopneumoniae extracellular vesicles ranges from 120 nm to 220 nm, and the mycoplasma hyopneumoniae extracellular vesicles are extracted from a mycoplasma hyopneumoniae culture. The mycoplasma hyopneumoniae extracellular vesicle provided by the invention is used for preventing mycoplasma hyopneumoniae infection after being used as a vaccine for immunization, reducing the lung lesion index and reducing the tissue pathogen load; the pig body can be induced to generate specific IgG antibodies, sIgA antibodies, IFN-gamma and IL-17 cell factors, and peripheral blood and lung mononuclear cell proliferation can be stimulated.

The invention discloses an antigen expression vector, a monkey pox virus mRNA vaccine and a composition, and relates to the technical field of monkey pox vaccines. The bivalent and tetravalent mRNA vaccines provided by the invention jointly express a combination of antigens from both IMV and EEV, and can provide sufficient protection against poxvirus attack. After the mRNA vaccine provided by the invention is injected into a mouse model, obvious body fluid and cellular immune response is shown, a body can be stimulated to quickly generate a specific IgG antibody within 2-4 weeks, and B lymphocytes can be stimulated to generate a high-level neutralizing antibody. In addition, the vaccine provided by the invention is simple to prepare, can simultaneously express a plurality of antigens, is strong in immunogenicity, and has good candidate vaccine potential.

The invention belongs to the field of biology, and discloses application of a Lawsonia intracellularis outer membrane protein MltA protein in preparation of vaccines and diagnostic kits, the protein is used as an antigen to prepare the Lawsonia intracellularis vaccine, and the risk that pigs are infected with porcine ileitis can be effectively reduced; meanwhile, the titer of the MltA protein specific IgG antibody can reach 1: 1638400, and the MltA protein specific IgG antibody can be used as a core antigen of a subunit vaccine and a key component of a high diagnostic reagent at the same time and is a potential anti-LI drug target.

This invention discloses the application of β-Hordothionin, its active fragment, or derivatives as intramolecular adjuvants, specifically involving a polypeptide derived from β-Hordothionin, the amino acid sequence of which is shown in SEQ ID NO.1, and the polynucleotide sequence of which is shown in SEQ ID NO.2. The polypeptide is fused with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and expressed, significantly enhancing the immunogenicity of the antigen. Experiments show that immunization of mice with the RBD-β-Hordothionin fusion protein induces a 1000-fold increase in specific IgG antibody titers compared to the RBD antigen alone. This fusion protein can be industrially prepared and can be used to enhance the immunogenicity of vaccine antigens.

The invention provides a method for detecting a specific IgG antibody in SD rat serum, and belongs to the technical field of biological detection. The detection method special for the SD rat serum sample is established, the operation process is standard, the result is stable and reliable, matrix interference can be effectively eliminated, and specific recognition and detection of a target antibody are achieved; the application of the method provides key technical support for preclinical efficacy and immunogenicity evaluation of related biopharmacy, significantly improves the accuracy and comparability of experimental data, and has positive significance in promoting the research and development process of drugs.

The application provides a food-specific IgG antibody detection kit and application thereof, 57 kinds of foods are grouped, any one of four groups of food antigens will produce cross reaction with the antibody corresponding to any other group of food antigens, any one kind of antigen in any one group of food antigens does not produce cross reaction with the antibody corresponding to any other kind of antigen, and thus cross reaction possibly existing in the case of large flux optimization experiment is avoided, so that the detection result is accurate; a blocking agent is added to completely eliminate cross interference; microspheres coupled with anti-human IgG2 antibody are added in the mixed solution of capture microspheres coupled with food antigens in each group for quality control, and the detection result of the quality control microspheres can be used to judge the effectiveness of the kit and the correctness of the experimental operation in real time. A blocking agent suitable for the kit system of the application is found, no false positive appears in 100 parallel tests; the calibration curve is obtained by testing the four combinations only once, and the corresponding content of 57 kinds of food-specific IgG antibodies is obtained; and the application has good application prospect.

The invention discloses application of Macranthoidin B in a vaccine adjuvant, relates to application of Macranthoidin B, and belongs to the technical field of biological medicines. The invention mainly aims at providing a brand new application of the Macranthoidin B, namely the application of the Macranthoidin B in preparation of a vaccine adjuvant. The invention provides an application of Macranthoidin B in preparation of a vaccine adjuvant. The Macranthoidin B is used as an active component of a vaccine adjuvant in the vaccine composition. When the Macranthoidin B is combined with a protein antigen (ovalbumin) for use, the Macranthoidin B can induce to generate adaptive immune responses which are obviously better than reference adjuvants QS-21 and R848, and the adaptive immune responses comprise higher-level antigen-specific IgG, more antigen-specific memory B cells and stronger antigen-specific T cell reactions. Meanwhile, the Macranthoidin B does not cause obvious hepatotoxicity in an effective dose, and has better safety. The invention provides a new candidate compound for developing an efficient and safe vaccine adjuvant.

The invention belongs to the technical field of enzyme-linked immunosorbent assay, and relates to a kit for animal epidemic disease detection. The invention provides a kit for animal epidemic disease detection, the kit is an enzyme linked immunosorbent assay kit, the enzyme linked immunosorbent assay kit comprises a diluent for sample dilution, and the diluent comprises 5-10 g / L of bovine serum albumin and 10-30 g / L of a bovine serum albumin-polymer coupling body. According to the invention, the technical problem of high background signal or false positive caused by adsorption of non-specific IgG to a solid-phase carrier when an enzyme-linked immunosorbent assay kit is used for enzyme-linked immunosorbent assay (ELISA) detection is solved.

Developing an effective HIV-1 vaccineis contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, vaccine candidates such as LC3.SOSIP(w) and LC3.SOSIP(s) showed promising results in New Zealand white rabbits. These candidates elicited significantly higher Env-specific IgG levels than controls, demonstrated high affinity for SOSIP antigens in ELISA binding assays, and achieved broad neutralizing capabilities against multiple HIV-1 pseudoviruses in TZM-bl neutralization assays. In conclusion, HIV Env antigen can be adaptively targeted to LC as a trimer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such constructs as LC targeting HIV-1 vaccines.